




**HFA**  
Heart Failure  
Association

# Heart Failure

& World Congress on  
Acute Heart Failure

# 2021



**POST CONGRESS REPORT**

Organised by the Heart Failure Association of the ESC

**29 June  
to 1 July**

**ONLINE  
CONGRESS**

[www.escardio.org/heartfailure](http://www.escardio.org/heartfailure)  
[#HeartFailure2021](https://twitter.com/HeartFailure2021)

 **ESC**  
European Society  
of Cardiology

# Table of contents

1. INTRODUCTION .....	4
a. Quick facts & figures .....	4
b. Heart Failure 2021 CPC .....	4
c. Event schedule .....	5
2. EVENT PLATFORM .....	6
a. Overview .....	6
b. HF Studio in Florence .....	7
c. Interactivity .....	7
i. Forum during scientific sessions .....	7
ii. Abstract gallery .....	7
iii. General feedback on session .....	7
iv. Scientific content poll to engage audience .....	7
v. Live zoom discussion rooms.....	7
d. Resources & VOD .....	8
3. SCIENTIFIC AND EDUCATIONAL PROGRAMME .....	9
a. Overview .....	9
b. Faculty - Activities / Roles .....	11
c. Scientific and educational Programme .....	15
d. Abstracts & clinical cases .....	29
e. Live zoom abstracts.....	36
f. Publications (abstract supplement) .....	38
4. INTERLUDES .....	39
a. Slides (waiting, transition, technical) .....	39
b. Interludes (promo videos) and daily countdowns .....	39
c. Intro/outro .....	40
d. Advertorial Broadcasts.....	41
5. INDUSTRY .....	42
a. Exhibition .....	42
b. Industry Sponsored Sessions .....	44
c. Sponsorship.....	45
i. Eblasts .....	45
ii. Banners .....	45
iii. Advert Broadcast.....	45
6. REGISTRATION, ATTENDANCE & PARTICIPATION .....	46
a. Registration .....	46

b.	Live programme attendance & participation.....	46
7.	E-COMMUNICATION.....	51
a.	Promotional ecampaigns .....	51
b.	Social media .....	60
iv.	Twitter.....	60
v.	Facebook.....	62
vi.	LinkedIn.....	62
vii.	Instagram .....	63
viii.	Metrics definition.....	63
c.	General Results .....	64
8.	PRESS.....	66
a.	Key numbers .....	66
b.	Charts .....	67
c.	Clippings.....	68

# 1. INTRODUCTION

## a. Quick facts & figures

### CME credits

17 CME credits from UEMS

### Event platform

4 channels live streamed

**1 full live from the studio in Florence**

3 channels for pre-recorded sessions

On-demand content

### 8169 total registrations

**123** countries represented

**44.5 %** of registrants under 40

**44.5 %** of registrants were female

**237** Faculty members (for 529 Faculty roles) from 40 countries

### Scientific sessions

**88** scientific and educational sessions

**26** abstract-based sessions

**25** Satellite Symposia

### Abstracts & clinical cases submitted

**1156** abstracts submitted and **154** clinical cases

**971** abstracts accepted and **111** clinical cases accepted

### Other

No printed PAAG

No Mobile App

No printed programme

## b. Heart Failure 2021 CPC

### Heart Failure 2021 Chair

Prof. Massimo Francesco Piepoli (Italy)

### Heart Failure 2021 Co-Chair

Prof. Maurizio Volterrani (Italy)

### **c. Event schedule**

#### **DAY BEFORE THE CONGRESS: Monday 28 June**

**09:00** Opening of the congress platform.

Access to abstract gallery, virtual exhibition etc...

#### **DAY 1: Tuesday 29 June**

**08:00:** Inaugural session LIVE from the HF Studio in Florence

**08:20 – 12:25:** Live stream (4 channels)

1 LIVE Channel - 3 scientific sessions (incl. Guidelines in mainstream)

3 live streamed channels - 6 Pre-recorded sessions

8 Industry sessions – non-exclusive slots

**14:10 – 14:55:** Oral Abstract sessions (6 slots – zoom)

**15:00 – 20:55:** Live stream (1 channel mainstream)

5 LIVE scientific sessions

2 Industry sessions – exclusive slots

#### **DAY 2: Wednesday 30 June**

**08:00 - 12:05:** Live stream (4 channels)

1 LIVE Channel - 3 scientific sessions

3 live streamed channels - 9 Pre-recorded sessions

8 Industry sessions – non-exclusive slots

**14:10 - 14:55:** Oral Abstract sessions (6 slots – zoom)

**14:10 – 19:20 :** Live stream (4 channels)

1 LIVE Channel - 4 scientific sessions

3 live streamed channels - 9 Pre-recorded sessions

2 Industry sessions – exclusive slots

#### **DAY 3: Thursday 1<sup>st</sup> July**

**08:00 – 12:05:** Live stream (4 channels)

1 LIVE Channel - 3 scientific sessions

3 live streamed channels - 6 Pre-recorded sessions

8 Industry sessions – non-exclusive slots

**14:10 - 14:55:** Oral Abstract sessions (6 slots – zoom)

**14:10 – 21:45:** Live stream (1 channel mainstream)

5 LIVE scientific sessions

2 Industry sessions – exclusive slots

Suppliers:

CYIM: Industry Sessions + live sessions Florence + Streaming

STS Communication: Studio

K4: Pre-recorded sessions

Studio Arancio: Studio furniture

## 2. EVENT PLATFORM

### a. Overview

The navigation bar contains four white cards with gold icons and text:

- Programme Search**: Browse the scientific programme and see what you don't want to miss. [Start now ->](#)
- Speakers**: Discover the leading experts presenting at this event. [Start now ->](#)
- Latest science**: Access abstracts and clinical cases. [Start now ->](#)
- Schedule Overview**: See what's planned by day in each channel. [Start now ->](#)



[Schedule overview](#) [Search in the programme](#) [My Programme](#)

The main content area is titled "Programme" and includes a search bar with the text "Search through all the scientific sessions and bookmark your favourites." Below the search bar are filters for "Sessions (77)", "Industry Sessions (26)", "Speakers (332)", and "Abstracts (10)". There are also dropdown menus for "Days", "Types and tracks", and "Topics", along with a "CLEAR" button. The results are displayed in a grid of cards, each with a time slot, a title, a description, and a "SEE DETAILS" link.

Time	Title	Description	Action
25 June - 08:20	Cardiomyopathies: one of the leading causes of heart failure		<a href="#">SEE DETAILS -&gt;</a>
25 June - 08:30	Heart failure epidemiology: surveys and registries 2021		<a href="#">SEE DETAILS -&gt;</a>
29 June - 08:26	Multidisciplinary interventions in acute heart failure: clinical case presentations		<a href="#">SEE DETAILS -&gt;</a>
29 June - 08:20	SGLT2 in heart failure		<a href="#">SEE DETAILS -&gt;</a>
25 June - 09:50			
29 June - 10:50			
29 June - 09:50			
29 June - 10:50			

## b. HF Studio in Florence



## c. Interactivity

### i. Forum during scientific sessions

- ✓ Delegates could ask questions and interact during the sessions
- ✓ For the pre-recorded sessions: Presenters were asked to connect online to answer questions during scientific sessions
- ✓ For the pre-recorded sessions: Presenters were asked to connect online to answer questions
- ✓ For the live sessions: questions answered orally by the session host

#### NEW:

- ✓ Up to 3 Scientific polls/ sessions on top of the Marketing survey at the end
- ✓ Questions and comments from the audience made visible during live sessions.

Supplier: Pigeonhole

### ii. Abstract gallery

When viewing an abstract, delegates could ask a question to the abstract submitter.

### iii. General feedback on session

Delegates were able to give us feedback on their level of satisfaction after each session (via the forum).

### iv. Scientific content poll to engage audience

Scientific polls were created by the speakers (poll launched via the forum)

### v. Live zoom discussion rooms

Best rated abstracts were featured in live discussions rooms (Zoom).

#### **d. Resources & VOD**

Sessions: available on the event platform within the hour after the session

Until 15/07/2021: All content (VOD) available to registered delegates on the event platform (2 Weeks)

From 16/07/2021: Resources only available to HFA paying members via ESC 365



### 3. SCIENTIFIC AND EDUCATIONAL PROGRAMME

#### a. Overview

**TOTAL sessions in HF 2021 Online & On demand = 114**

*Detailed breakdown available below*

#### **88 sessions - Scientific and Educational Programme**

Session type	# sessions
Case-Based Session	5
Debate Session	6
HFA Focus	1
How To ...	5
Special Event	1
Special Session	30
Symposium	40
<b>Grand Total</b>	<b>88</b>

#### **26 sessions – Abstract-based programme**

Session type	# sessions
Abstract Sessions	16
Award Sessions	4
Clinical Cases	3
Clinical Trial Update	1
e-posters	1
Registry Session	1
<b>Grand Total</b>	<b>26</b>

#### **27 – Industry Programme**

Session type	# sessions
Satellite Symposium	25
Tutorials	2
<b>Grand Total</b>	<b>27</b>

*For full Industry Programme report – see [Industry section](#)*

## Channels per day

The programme was articulated around 4 channels per day to feature the topic related sessions + on demand content available throughout the event.

### Tuesday 29 June

- Full-day channel - HF Studio (Live sessions only)
- Morning channel - Chronic Heart Failure (pre-recorded sessions only)
- Morning channel - Acute Heart Failure (pre-recorded sessions only)
- Morning channel - Specials (pre-recorded sessions only)

### Wednesday 30 June

- Full-day channel - HF Studio (Live sessions only)
- Full-day channel - Chronic Heart Failure (pre-recorded sessions only)
- Full-day channel - Acute Heart Failure (pre-recorded sessions only)
- Full-day channel - Specials (pre-recorded sessions only)

### Thursday 1 July

- Full-day channel - HF Studio (Live sessions only)
- Morning channel - Chronic Heart Failure (pre-recorded sessions only)
- Morning channel - Heart Failure (pre-recorded sessions only)
- Morning channel - Specials (pre-recorded sessions only)

## Broadcast & on-demand content:

- **40 pre-recorded sessions** were broadcast on the “pre-recorded” channels or made available on demand.
- **24 self-recorded sessions** were made available on demand
- **28 Live sessions** were broadcast live on the HF Studio channel
- **18 Live abstract & clinical case discussion rooms** were organised via zoom and broadcast on the congress platform.

Session Type	29-Jun	30-Jun	1-Jul	On demand throughout the event
e-posters				1
Abstract Sessions	5	6	5	
Clinical Cases	1		1	1
Award Sessions				4
Clinical Trial Update				1
Registry Session				1
Case-Based Session	1	2	1	1
Debate Session		3	3	
HFA Focus	1			
How To ...			3	2
Special Event	1			
Special Session	7	8	9	6
Symposium	7	13	2	18
<b>Grand Total</b>	<b>23</b>	<b>32</b>	<b>24</b>	<b>35</b>

### Contributors to the programme – with breakdown Faculty + Presenters + Assigned Presenter

#### 237 Faculty

651 Abstract Presenters + 92 Clinical Case Presenters + 14 Clinical Trial updates Presenters + 9 Registry Presenters  
=> 1003 contributors to the programme

#### b. Faculty - Activities / Roles

#### 529 Faculty Roles (excluding Industry and special events)

- 190 Hosts roles
- 283 Speaker roles
- 11 Judge abstract roles
- 14 Session Discussants
- 31 Abstract / clinical cases live session Moderators

Year	2018	2019	2020	Year	2021
<b>Faculty number of roles</b>	<b>670</b>	<b>639</b>	<b>510</b>	<b>Faculty number of roles</b>	<b>529</b>
Chairperson	233	232	169	Chairperson	190
Speaker	344	319	310	Speaker	283
Judges	20	15	4	Judges	11
Discussant	73	73	27	Discussant	14
				Live Abstract / Clinical Case Moderators	31
<b>Total number of Faculty</b>	<b>286</b>	<b>296</b>	<b>251</b>	<b>Total number of Faculty</b>	<b>237</b>

#### Number of Faculty

**237 Faculty Members** (excluding abstract & clinical cases Presenters and Industry)

## Role distribution per faculty

# roles	# Faculty
1	130
2	40
3	21
4	16
5+	30
<b>Grand Total</b>	<b>237</b>

## Gender representation

Gender	2019		2020		2021	
Female	68	23%	66	26%	55	23%
Male	228	77%	185	74%	182	77%
<b>Grand Total</b>	<b>296</b>	<b>100%</b>	<b>251</b>	<b>100%</b>	<b>237</b>	<b>100%</b>

## Age Table

Age range	# Faculty	%
35 and under	10	4%
36 to 40	24	10%
41 to 46	23	10%
47 to 57	72	30%
<b>58 to 68</b>	<b>82</b>	<b>35%</b>
69 and above	26	11%
<b>Grand Total</b>	<b>237</b>	<b>100%</b>

## Region

Faculty by Region	2019	%	2020	%	2021	%
<b>ESC</b>	<b>251</b>	<b>85%</b>	<b>211</b>	<b>84%</b>	<b>209</b>	<b>88%</b>
North America	31	10%	31	12%	19	8%
Asia Pacific	11	4%	8	3%	6	3%
South & Central America	2	1%	0	0%	2	1%
Africa (non ESC)	1	0%	1	0%	1	0%
<b>Grand Total</b>	<b>296</b>	<b>100%</b>	<b>251</b>	<b>100%</b>	<b>237</b>	<b>100%</b>

## Country by order of country representation

237 Faculty coming from 40 different countries

Country	# Faculty per country
Italy	60
Germany	32
UK & Northern Ireland	27
USA	17
France	13
Greece	9
The Netherlands	9
Sweden	9
Spain	7
Switzerland	5
Austria	4
Poland	4
Belgium	3
Israel	3
Canada	2
Croatia	2
Denmark	2
Egypt	2
Lebanon	2
Portugal	2
Romania	2
Russia	2
Serbia	2
Argentina	1
Australia	1
Brazil	1
Bulgaria	1
China	1
Cyprus	1
Czechia	1
Finland	1
Hungary	1
India	1
Japan	1
Kazakhstan	1
Lithuania	1
Norway	1
Singapore	1
Slovenia	1
South Africa	1
<b>Grand Total</b>	<b>237</b>

### **Faculty invited onsite in Florence, Italy**

All Faculty involved in live sessions have been invited to Florence (HF Studio).

**In total, 76 Faculty have been invited** (32 Board members + 44 Faculty)

=> **36 Faculty** (21 Board members + 15 Faculty) **came to Florence.**

## c. Scientific and educational Programme

### GENERAL OVERVIEW – Tuesday 29 June

Start	End	Duration	Channel 1 HF Studio	Start	End	Duration	Channel 2 Chronic Heart Failure Pre-recorded sessions	Channel 3 Acute Heart Failure Pre-recorded sessions	Channel 4 Specials Pre-recorded sessions
8:00	8:15	0:15	900 - LIVE - Inaugural session						
8:15	8:20	0:05	INTERLUDE						
8:20	9:10	0:50	901 - Cardiomyopathies: one of the leading causes of heart failure	8:20	9:05	0:45	152 - SGLT2i in Heart Failure	124 - Multidisciplinary interventions in acute heart failure: clinical case presentations.	134 - Heart failure epidemiology: surveys and registries 2021
9:10	9:15	0:05	INTERLUDE						
9:15	9:45	0:30	Non-exclusive Industry session	9:15	9:45	0:30	Non-exclusive Industry session	Non-exclusive Industry session	Non-exclusive Industry session
9:45	9:50	0:05	INTERLUDE						
9:50	10:40	0:50	922 - Current pharmacological treatment of heart failure with mid-range ejection fraction	9:50	10:35	0:45	161 - HFA Focus: challenging clinical scenarios in heart failure	118 - Heart Team evaluation in valvular heart diseases	103 - COVID-19 and cardiorespiratory failure, from pathophysiology to clinical practice
10:40	10:45	0:05	INTERLUDE						
10:45	11:30	0:45	911 - LIVE - Heart Failure Guidelines 2021: pharmacological treatment						
11:30	11:40	0:10	INTERLUDE						
11:40	12:25	0:45	Non-exclusive Industry session	11:40	12:25	0:45	Non-exclusive Industry session	Non-exclusive Industry session	Non-exclusive Industry session
12:25	14:00		BREAK						
14:10	14:55	0:45	Implications and messaging about HVAD withdrawal by Medtronic - effect on patients, and the advanced HF field	14:00	15:00	1:00	6 Rapid fire abstract zoom rooms in parallel		
14:55	15:00	0:05	INTERLUDE						
15:00	16:00	1:00	912 - Expert opinion on heart failure management: drug titration						
16:00	16:05	0:05	INTERLUDE						
16:05	16:35	0:30	Exclusive Industry Live session						
16:35	16:40	0:05	INTERLUDE						
16:40	17:40	1:00	913 - Late breaking trial 1						
17:40	17:45	0:05	INTERLUDE						
17:45	18:30	0:45	Exclusive Industry Live session						
18:30	18:35	0:05	INTERLUDE						
18:35	19:35	1:00	909 - Heart failure specifics in chronic kidney disease						
19:35	19:40	0:05	INTERLUDE						
19:40	20:40	1:00	902 - Role of SGLT2 inhibitors in heart failure: beyond diabetes						
20:40	20:45	0:05	INTERLUDE						
20:45	20:55	0:10	916 - Wrap-up day 1						
20:55	21:00	0:05	INTERLUDE						
21:00	21:45	0:45	REPLAY 911 - Heart Failure Guidelines 2021: pharmacological treatment						

## GENERAL OVERVIEW – Wednesday 30 June

Start	End	Duration	Channel 1 HF Studio	Start	End	Duration	Channel 2 Chronic Heart Failure Pre-recorded sessions	Channel 3 Acute Heart Failure Pre-recorded sessions	Channel 4 Specials Pre-recorded sessions
8:00	8:50	0:50	904 - Controversies in primary prevention of sudden cardiac death in 2021: should class I recommended for ICD be reconsidered?	8:00	8:45	0:45	102 - Treating common comorbidities (iron deficiency and sleep apnoea)	120 - Diagnostic and prognostic value of biomarkers in acute heart failure	136 - Implementation science: barriers to HFrEF therapy
8:50	8:55	0:05	INTERLUDE	8:45	8:55	0:10	INTERLUDE		
8:55	9:45	0:50	906 - Expert opinion in heart failure management - Heart failure with preserved ejection fraction	8:55	9:40	0:45	181 - Rapid Parade of devices: emerging treatment options in heart failure (Part 1)	144 - When prescribing the right drugs is not enough	140 - Gene therapy, Genome Editing and beyond – Are we seeing the birth of a new generation of medicines?
9:45	9:50	0:05	INTERLUDE	9:40	9:50	0:10	INTERLUDE		
9:50	10:20	0:30	Non-exclusive Industry session	9:50	10:20	0:30	Non-exclusive Industry session	Non-exclusive Industry session	Non-exclusive Industry session
10:20	10:25	0:05	INTERLUDE	10:20	10:25	0:05	INTERLUDE		
10:25	11:15	0:50	920 - Expert opinion in heart failure management - Disease management	10:25	11:10	0:45	145 - Cardiac resynchronisation therapy, areas of debate	131 - Peri-discharge period after acute heart failure: the prime time to bother about comorbidities.	138 - Cardiac tissue engineering: from the bench to bedside. Are we ready?
11:15	11:20	0:05	INTERLUDE	11:10	11:20	0:10	INTERLUDE		
11:20	12:05	0:45	Non-exclusive Industry session	11:20	12:05	0:45	Non-exclusive Industry session	Non-exclusive Industry session	Non-exclusive Industry session
12:05	14:00		BREAK	12:05	14:00		BREAK		
14:10	14:55	0:45	155 - Life-time achievement 2020	14:00	15:00	1:00	6 Rapid fire abstract zoom rooms in parallel		
14:55	15:00	0:05	INTERLUDE						
15:00	15:50	0:50	905 - Controversies in 2021 OMT: should SGLT-2i and ARNI now be considered first line treatments in HFrEF?	15:00	15:45	0:45	112 - Challenges in cardiac rehabilitation in chronic heart failure	122 - Treating valvular heart disease in acute heart failure	972 - e-Health and social media in heart failure care: pro and con
15:50	15:55	0:05	INTERLUDE	15:45	15:55	0:10	INTERLUDE		
15:55	16:45	0:50	914 - Late breaking trial 2	15:55	16:40	0:45	149 - HoT session - HFrEF treatment: not so easy as it seems, Part 1	117 - New concepts in the management of cardiogenic shock	113 - Digital health and telemedicine in heart failure
16:45	16:50	0:05	INTERLUDE	16:40	16:50	0:10	INTERLUDE		
16:50	17:20	0:30	Exclusive Industry Live session						
17:20	17:25	0:05	INTERLUDE	17:20	17:25	0:05	INTERLUDE		
17:25	18:15	0:50	918 - Expert opinion in heart failure management - Drugs	17:25	18:10	0:45	153 - Prevention from heart failure 1: role of risk factors	128 - Contemporary management of sudden cardiac death in patients with heart failure	101 - Advanced HFrEF: what are the options when drug therapy is maximised?
18:15	18:20	0:05	INTERLUDE	18:10	18:20	0:10	INTERLUDE		
18:20	19:05	0:45	Exclusive Industry Live session						
19:05	19:10	0:05	INTERLUDE						
19:10	19:20	0:10	917 - Wrap-up day 2						



## GENERAL OVERVIEW – Thursday 1<sup>st</sup> July

Start	End	Duration	Channel 1 HF Studio	Start	End	Duration	Channel 2 Chronic Heart Failure Pre-recorded sessions	Channel 3 Heart Failure Pre-recorded sessions	Channel 4 Specials Pre-recorded sessions
8:00	8:50	0:50	907 - How to optimise treatment according to patient profile in HFREF	8:00	8:45	0:45	126 - Practical aspects on ventricular assist devices	154 - Prevention from heart failure 2: population attributable risk around the world	151 - Heart Failure Association patient profiling
8:50	8:55	0:05	INTERLUDE	8:45	8:55	0:10	INTERLUDE		
8:55	9:45	0:50	903 - Tailored therapy in heart failure: which, how and when	8:55	9:40	0:45	182 - Rapid Parade of devices: emerging treatment options in heart failure (Part 2)	107 - Is HFpEF a disease of women? From biological to epidemiological evidence	147 - Pragmatic trials are here to stay
9:45	9:50	0:05	INTERLUDE	9:40	9:50	0:10	INTERLUDE		
9:50	10:20	0:30	Non-exclusive Industry session	9:50	10:20	0:30	Non-exclusive Industry session	Non-exclusive Industry session	Non-exclusive Industry session
10:20	10:25	0:05	INTERLUDE	10:20	10:25	0:05	INTERLUDE		
10:25	11:15	0:50	908 - Heart failure disease management programs: is losing weight a good or a bad thing?	10:25	11:10	0:45	150 - HoT session - HFREF treatment: not so easy as it seems, Part 2	132 - Do we improve quality of life in patients with heart failure?	961 - How to optimise implementation of cardiac resynchronisation therapy
11:15	11:20	0:05	INTERLUDE	11:10	11:20	0:10	INTERLUDE		
11:20	12:05	0:45	Non-exclusive Industry session	11:20	12:05	0:45	Non-exclusive Industry session	Non-exclusive Industry session	Non-exclusive Industry session
12:05	14:00	BREAK							
14:10	14:55	0:45	156 - Life-time achievement 2021	14:00	15:00	1:00	6 Rapid fire abstract zoom rooms in parallel		
14:55	15:00	0:05	INTERLUDE						
15:00	16:00	1:00	919 - Expert opinion in heart failure management - Devices						
16:00	16:05	0:05	INTERLUDE						
16:05	16:35	0:30	Exclusive Industry Live session						
16:35	16:40	0:05	INTERLUDE						
16:40	17:40	1:00	915 - Late breaking trial 3						
17:40	17:45	0:05	INTERLUDE						
17:45	18:30	0:45	Exclusive Industry Live session						
18:30	18:35	0:05	INTERLUDE						
18:35	19:35	1:00	910 - Expert opinion in heart failure management - Heart failure and ischaemic heart disease						
19:35	19:40	0:05	INTERLUDE						
19:40	20:40	1:00	921 - Expert opinion in heart failure management - Imaging						
20:40	20:45	0:05	INTERLUDE						
20:45	21:45	1:00	923 - Heart Failure 2021 Highlights						

**Sessions by topic (EXCLUDING Industry sessions and Special Event)**

Topic	# Session
10 - Atrial Fibrillation (AF)	1
13 - Ventricular Arrhythmias and Sudden Cardiac Death (SCD)	1
13.4 - Treatment	1
14 - Device Therapy	1
15 - Chronic Heart Failure	33
15.1 - Pathophysiology and Mechanisms	3
15.1.10 - Heart Failure with Preserved Ejection Fraction (HFpEF)	2
15.2 - Epidemiology, Prognosis, Outcome	2
15.3 - Diagnostic Methods	1
15.3.2 - Imaging	2
15.4 - Treatment	5
15.4.2 - Pharmacotherapy	1
15.4.3 - Rehabilitation	1
15.4.5 - Cardiac Resynchronisation Therapy (CRT)	2
15.4.6 - Ventricular Assist Devices	2
15.4.7 - Heart Transplantation	1
15.4.9 - Multidisciplinary Interventions	1
16 - Acute Heart Failure	4
16.3.1 - Biomarkers	1
16.4 - Treatment	1
16.4.2 - Nonpharmacological Treatment	1
16.4.2.1 - Circulatory Support	1
16.4.3 - Multidisciplinary Interventions	2
17 - Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)	1
19 - Acute Cardiac Care	2
19.4 - Cardiogenic Shock	1
20 - Valvular Heart Disease	1
20.4 - Treatment	1
20.4.2 - Intervention	1
22 - Myocardial Disease	2
26 - Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure	1
33 - Risk Factors and Prevention	3
34.1 - Exercise Testing	1
35 - Cardiovascular Disease in Special Populations	1
36 - Pharmacology and Pharmacotherapy	2
37 - Cardiovascular Nursing and Allied Professions	5
38 - e-Cardiology/Digital Health	1
38.6 - Hospital Information Systems, Electronic Medical Records, Clinical Decision Support	1
40 - Research Methodology	1
40.2 - Big Data Analysis	1
40.3 - Cardiovascular Epidemiology	1
40.4 - Trial Design	1
41 - Basic Science	2
41.2 - Cardiac Biology and Physiology	2
41.2.8 - Leukocytes, Inflammation, Immunity	1

41.3.11 - Gene Therapy, Cell Therapy	1
41.3.12 - Biomarkers	1
41.3.3 - Heart Failure	2
41.4.1 - Stem Cells, Cell Cycle, Cell Senescence, Cell Death	1
90.2 - Heart Failure Association (HFA)	5
<b>Grand Total</b>	<b>113</b>

## Joint sessions

### 5 Pre-recorded joint sessions:

#### **161 - HFA focus: challenging clinical scenarios in heart failure**

Joint session with the Heart Failure Society of America (HFSA) and the Japanese Heart Failure Society (JHFS).

#### **965 - Heart failure and brain function: adding insult to injury**

Joint session with the ESC Council on Stroke

#### **962 - Cardiac rhythm management devices in heart failure: areas of debate**

Joint session with the European Heart Rhythm Association (EHRA)

#### **961 - How to optimise implementation of cardiac resynchronisation therapy**

Joint session with the European Heart Rhythm Association (EHRA)

#### **972 - e-Health and social media in heart failure care: pro and con**

Joint session with the Association of Cardiovascular Nursing and Allied Professions (ACNAP)

#### **911 - Heart Failure Guidelines 2021: pharmacological treatment**

### A joint ESC/HFA Session

### Capture of Content – Live sessions

#### **28 Live sessions**

**Supplier: CYIM / STS**

For the Live Sessions, Faculty did not attend any content rehearsals prior the live event. Faculty joining remotely were asked to connect 1 hour before the start of the live session. Faculty onsite were asked to come 1 hour before the start of the live session in the briefing room. All together, they reviewed the scenario and underwent final technical checks with the supplier.


No specific functionalities (such as voting, etc) were used during the live sessions.

Session	Type	Title	Room location	Date	StartTime
900	Special Event	Heart Failure 2021 - Inaugural Session	All active channel	29/06/2021	29/06/2021 08:00
901	Symposium	Cardiomyopathies: one of the leading causes of heart failure	HF Studio	29/06/2021	29/06/2021 08:20
922	Symposium	Current pharmacological treatment of heart failure with mid-range ejection fraction	HF Studio	29/06/2021	29/06/2021 09:50
911	Special Session	Heart Failure Guidelines 2021: pharmacological treatment	All active channel	29/06/2021	29/06/2021 10:45
924	Special Session	Implications and messaging about HVAD withdrawal by Medtronic - effect on patients, and the advanced HF field	HF Studio	29/06/2021	29/06/2021 14:10
912	Special Session	Expert opinion on heart failure management: drug titration	HF Studio	29/06/2021	29/06/2021 15:00
913	Special Session	Late-Breaking Trials 1	HF Studio	29/06/2021	29/06/2021 16:40
909	Symposium	Heart failure specifics in chronic kidney disease	HF Studio	29/06/2021	29/06/2021 18:35
902	Symposium	Role of SGLT2 inhibitors in heart failure: beyond diabetes	HF Studio	29/06/2021	29/06/2021 19:40
916	Special Session	Wrap-up Day 1	HF Studio	29/06/2021	29/06/2021 20:45
925	Special Session	Heart Failure Guidelines 2021: pharmacological treatment	HF Studio	29/06/2021	29/06/2021 21:00
904	Debate Session	Controversies in primary prevention of sudden cardiac death in 2021: should Class I recommended for ICD be reconsidered?	HF Studio	30/06/2021	30/06/2021 08:00
906	Special Session	Expert opinion on heart failure management: heart failure with preserved ejection fraction	HF Studio	30/06/2021	30/06/2021 08:55
920	Special Session	Expert opinion on heart failure management: disease management	HF Studio	30/06/2021	30/06/2021 10:25
155	Special Session	Lifetime achievement 2020	HF Studio	30/06/2021	30/06/2021 14:10
905	Debate Session	Controversies in 2021 OMT: should SGLT2i and ARNI now be considered first line treatments in HFrEF?	HF Studio	30/06/2021	30/06/2021 15:00
914	Special Session	Late-Breaking Trials 2	HF Studio	30/06/2021	30/06/2021 15:55
918	Special Session	Expert opinion on heart failure management: drugs	HF Studio	30/06/2021	30/06/2021 17:25
917	Special Session	Wrap-up Day 2	All active channel	30/06/2021	30/06/2021 19:10
907	How To ...	How to optimise treatment according to patient profile in HFrEF	HF Studio	01/07/2021	01/07/2021 08:00
903	Debate Session	Tailored therapy in heart failure: which, how and when	HF Studio	01/07/2021	01/07/2021 08:55
908	Debate Session	Heart failure disease management programs: is losing weight a good or a bad thing?	HF Studio	01/07/2021	01/07/2021 10:25
156	Special Session	Lifetime achievement 2021	HF Studio	01/07/2021	01/07/2021 14:10
919	Special Session	Expert opinion on heart failure management: devices	HF Studio	01/07/2021	01/07/2021 15:00
915	Special Session	Late-Breaking Trials 3	HF Studio	01/07/2021	01/07/2021 16:40
910	Special Session	Expert opinion on heart failure management: heart failure and ischaemic heart disease	HF Studio	01/07/2021	01/07/2021 18:35
921	Special Session	Expert opinion on heart failure management: imaging	HF Studio	01/07/2021	01/07/2021 19:40
923	Special Session	Heart Failure 2021 highlights	HF Studio	01/07/2021	01/07/2021 20:45

Print screen of a live session – view of the HF Studio with remote and onsite Faculty during chairperson’s introduction => 2 chairs on the right side of the stage (1 onsite + 1 remote):



Print screen of a live session – view of the HF Studio with onsite speaker during his presentation – PIP view:



Print screen of a live session – view of the HF Studio with onsite speaker during their presentation – Studio view:

**HFA Heart Failure Association**

**MitraClip Expanded Indication**

- Secondary mitral regurgitation reduction
  - FDA approved new indication for MitraClip on March 14, 2019
  - "patients with normal mitral valves who develop heart failure symptoms and moderate-to-severe or severe mitral regurgitation because of diminished left heart function (commonly known as secondary or functional mitral regurgitation) despite being treated with optimal medical therapy"

#HeartFailure2021

3615 William Abraham  
USA

Expert opinion on heart failure management: devices

LIVE 0:30:55

Print screen of a live session – view of the HF Studio with remote speaker during their presentation – PIP view:

**MADIT II**

- 1232, LVEF<30% :ICD or OMT
- Post MI > 1 month, no prior VT/VF
- Mortality: ICD 14% , OMT 20%
- ACE-70%, BB-69%, MRA-0%, DIG-57%

**SCD-HeFT**

2521, CHF, LVEF≤35%  
50% DCM, NYHA II (70%);III (30%)  
60yrs; 77% ♂  
ACEI/ARB-97%, BB-92%, MRA-20%

Probability of Survival

Year

p=0.005

Moss et al. NEJM 2002; 346:877-83.

Mortality Rate

Months of Follow up

Bardy et al. NEJM 2005;352:225-37

Heart Failure 2021

3615 Theresa McDonagh  
UK

Expert opinion on heart failure management: devices


LIVE 0:52



Print screen of a live session – view of the HF Studio with remote speaker during their presentation – Studio view:



Print screen of a live session – view of the HF Studio with remote and onsite Faculty during panel discussion => 3 chairs on the right side of the stage (2 onsite + 1 remote), 3 speakers on the left side (2 onsite + 1 remote).



## Capture of Content – Pre-recorded sessions

### 40 pre-recorded sessions

#### Supplier: K4 Events

For most pre-recorded sessions, Faculty were invited to attend a content rehearsal, the recording meeting and to connect on the day of the broadcast for interaction with the audience via a Discussion Chat.

Session	Type	Title	Room location	Date	StartTime
101	Symposium	Advanced HFREF: what are the options when drug therapy is maximised?	Specials	30/06/2021	30/06/2021 17:25
102	Symposium	Treating common comorbidities (iron deficiency and sleep apnoea)	Chronic Heart Failure	30/06/2021	30/06/2021 08:00
103	Symposium	COVID-19 and cardiorespiratory failure, from pathophysiology to clinical practice	Specials	29/06/2021	29/06/2021 09:50
107	Symposium	Is HFpEF a disease of women? From biological to epidemiological evidence	Heart Failure	01/07/2021	01/07/2021 08:55
112	Symposium	Challenges of cardiac rehabilitation in chronic heart failure	Chronic Heart Failure	30/06/2021	30/06/2021 15:00
113	Symposium	Digital health and telemedicine in heart failure	Specials	30/06/2021	30/06/2021 15:55
117	Symposium	New concepts in the management of cardiogenic shock	Acute Heart Failure	30/06/2021	30/06/2021 15:55
118	Symposium	Heart Team evaluation in valvular heart diseases	Acute Heart Failure	29/06/2021	29/06/2021 09:50
120	Symposium	Diagnostic and prognostic value of biomarkers in acute heart failure	Acute Heart Failure	30/06/2021	30/06/2021 08:00
122	Case-Based Session	Treating valvular heart disease in acute heart failure	Acute Heart Failure	30/06/2021	30/06/2021 15:00
124	Case-Based Session	Multidisciplinary interventions in acute heart failure: clinical case presentations	Acute Heart Failure	29/06/2021	29/06/2021 08:20
126	Case-Based Session	Practical aspects of ventricular assist devices	Chronic Heart Failure	01/07/2021	01/07/2021 08:00
128	Symposium	Contemporary management of sudden cardiac death in patients with heart failure	Acute Heart Failure	30/06/2021	30/06/2021 17:25
131	Symposium	Peridischarge period after acute heart failure: prime time to bother about comorbidities	Acute Heart Failure	30/06/2021	30/06/2021 10:25
132	How To ...	Do we improve quality of life in patients with heart failure?	Heart Failure	01/07/2021	01/07/2021 10:25
134	Symposium	Heart failure epidemiology: surveys and registries 2021	Specials	29/06/2021	29/06/2021 08:20
136	Symposium	Implementation science: barriers to HFREF therapy	Specials	30/06/2021	30/06/2021 08:00
138	Symposium	Cardiac tissue engineering from bench to bedside: are we ready?	Specials	30/06/2021	30/06/2021 10:25
140	Symposium	Gene therapy, genome editing and beyond: are we seeing the birth of a new generation of medicines?	Specials	30/06/2021	30/06/2021 08:55
144	Case-Based Session	When prescribing the right drugs is not enough	Acute Heart Failure	30/06/2021	30/06/2021 08:55
145	Debate Session	Cardiac resynchronisation therapy, areas of debate	Chronic Heart Failure	30/06/2021	30/06/2021 10:25
147	Debate Session	Pragmatic trials are here to stay	Specials	01/07/2021	01/07/2021 08:55
149	Symposium	HoT session – HFREF treatment: not so easy as it seems, Part 1	Chronic Heart Failure	30/06/2021	30/06/2021 15:55
150	Symposium	HoT session – HFREF treatment: not so easy as it seems, Part 2	Chronic Heart Failure	01/07/2021	01/07/2021 10:25
151	Special Session	Heart Failure Association patient profiling	Specials	01/07/2021	01/07/2021 08:00



152	Special Session	SGLT2i in heart failure	Chronic Heart Failure	29/06/2021	29/06/2021 08:20
153	Special Session	Prevention from heart failure 1: role of risk factors	Chronic Heart Failure	30/06/2021	30/06/2021 17:25
154	Special Session	Prevention from heart failure 2: population attributable risk around the world	Heart Failure	01/07/2021	01/07/2021 08:00
161	HFA Focus	HFA focus: challenging clinical scenarios in heart failure	Chronic Heart Failure	29/06/2021	29/06/2021 09:50
181	Special Session	Rapid parade of devices: emerging treatment options in heart failure, Part 1	Chronic Heart Failure	30/06/2021	30/06/2021 08:55
182	Special Session	Rapid parade of devices: emerging treatment options in heart failure, Part 2	Chronic Heart Failure	01/07/2021	01/07/2021 08:55
961	How To ...	How to optimise implementation of cardiac resynchronisation therapy	Specials	01/07/2021	01/07/2021 10:25
962	Symposium	Cardiac rhythm management devices in heart failure: areas of debate	On demand	29/06/2021	29/06/2021 08:00
965	Symposium	Heart failure and brain function: adding insult to injury	On demand	29/06/2021	29/06/2021 08:00
972	Symposium	e-Health and social media in heart failure care: pro and con	Specials	30/06/2021	30/06/2021 15:00
974	Special Session	Best papers of heart failure journals	On demand	29/06/2021	29/06/2021 08:00
980	Award Sessions	Young Investigator Award: clinical research	On demand	29/06/2021	29/06/2021 08:00
983	Award Sessions	Clinical Case Award	On demand	29/06/2021	29/06/2021 08:00
982	Award Sessions	Nursing Investigator Award	On demand	29/06/2021	29/06/2021 08:00
981	Award Sessions	Young Investigator Award: basic science	On demand	29/06/2021	29/06/2021 08:00

### Print screen of recording – Capture of the Chairpersons introduction

● New concepts in the management of cardiogenic shock

The screenshot displays three video feeds of chairpersons. From left to right: Ovidiu Chioncel (Romania), Offer Amir (Israel), and Yuhui Zhang (China). The recording title is 'New concepts in the management of cardiogenic shock'. A decorative logo is visible in the bottom left corner, and the hashtag #HeartFailure2021 is in the bottom right corner.

## Print screen of recording – Speaker during her presentation

● Treating valvular heart disease in acute heart failure


### HF department admission - diagnosis

- Decompensated chronic heart failure, NYHA class IV, with moderately reduced LVEF
- Symptomatic severe high gradient calcific aortic stenosis, with afterload mismatch
- Hypertension gr. III
- Mild anaemia with iron deficit
- Type 2 diabetes mellitus
- Mild form of dementia


  

- EUROSCORE II 5.55%
- frailty

intermediate operative risk



**Heart Failure 2021**  
The European Society of Cardiology



**Elena-Laura Antohi**  
Romania

#HeartFailure2021

## Print screen of recording – Faculty of a session during the Discussion time

● Treating valvular heart disease in acute heart failure

 <p><b>Ovidiu Chioncel</b> Romania</p>	 <p><b>Roberto Lorusso</b> The Netherlands</p>	 <p><b>John Parissis</b> Greece</p>
 <p><b>Elena-Laura Antohi</b> Romania</p>	 <p><b>Effie Polyzogopoulou</b> Greece</p>	 <p><b>Francesco Maisano</b> Switzerland</p>

#HeartFailure2021

## Capture of Content – Self-recorded sessions

### 24 pre-recorded sessions

Supplier: CYIM

Faculty self-registered their presentations, chairperson introduction / conclusion via the CYIM recorder through their MyESC profile. Chairperson introductions, speaker presentations and chairperson conclusions have then been packaged by CYIM. These sessions were available on demand on the event platform, consultable anytime throughout and after the congress.

### Print screen of recording – Capture of the Chairperson introduction


● Right ventricular dysfunction in heart failure: more burning questions than answers? - chairperson introduction.

## Right ventricular dysfunction in heart failure: More burning questions than answers?

**Sick right heart: do HFpEF and HFrEF differ in mechanisms?**  
Veli-Pekka Harjola, Finland

**Diagnostic algorithm for right heart failure: CPET for all patients?**  
Piergiuseppe Agostoni, Italy

**Management of right heart failure: what can we learn from PAH?**  
Marco Guazzi, Italy



John R TEERLINK  
(San Francisco - US)


Heart Failure 2021  
World Congress on  
Acute Heart Failure

#HeartFailure2021

Print screen of recording – Speaker during his presentation

● Echocardiography.

### The transition from heart failure with preserved ejection fraction (HFpEF) to heart failure with reduced ejection fraction (HFrEF) in arterial hypertension



Pre-clinical dysfxn    HFpEF    HFrEF

Greater absolute magnitude

Lower absolute magnitude

Hypertension

Progressive LV dysfunction

Early compensatory increase in circumferential function

Reduction in circumferential function associated with HF


LVEF

Circumferential deformation

Diastolic relaxation

Longitudinal deformation

Cikes and Solomon *Eur Heart J*, Volume 37, Issue 21, 1 June 2016, Pages 1642–1650, <https://doi.org/10.1093/eurheartj/ehv510>



Fausto Jose PINTO  
(Lisbon - PT)

#HeartFailure2021


● Imaging in heart failure - chairperson conclusion.

## Cardiac Imaging

### Assessment of RV function & PA Pressures

#### An obligatory element of echocardiography examination!

- ❖ RV structure & function
- ❖ RA size
- ❖ Estimate RV systolic function:
  - TAPSE <17mm
  - S' <9.5m/sec
  - PASP from TR velocity
  - 3D echo volumes is recommended
  - speckle tracking – specialised centres



Jelena CELUTKIENE  
(Vilnius - LT)

Heart Failure  
World Congress on  
Acute Heart Failure  
2021



#HeartFailure2021 ●

#### d. Abstracts & clinical cases

##### Figures – Acceptance rate

##### Overview Abstract & Clinical cases submitted/ accepted

	Status	2019		2020		2021	
		abstracts	clinical cases	abstracts	clinical cases	abstracts	clinical cases
Abstracts	Submitted	1 721	273	1864	225	1156	154
	Not validated & withdrawn	52	10	143	10	84	3
	Accepted	1 499	206	1580	155	971	111
	Rejected	222	67	141	60	103	43
	Accepted withdrawn	71	6	N/A	N/A	79	5
	% acceptance	87%	75%	85%	69%	84%	72%
Total presented & published on the abstract & clinical case platform						892	106
						998	

##### Top ten countries of accepted abstracts

Country	#ACCEPTED abstracts
Russian Federation	148
Portugal	138
Spain	103
Italy	65
UK & Northern Ireland	58
United States of America	51
Germany	32
Netherlands (The)	27
Poland	24
Ukraine	23

##### Top ten countries of accepted clinical cases

Country	# ACCEPTED clinical cases
Portugal	25
Spain	13
Italy	11
Romania	10
UK and Northern Ireland	9
Mexico	4
Germany	3
Ireland	3
Lebanon	3

## Reviewing committee

Graders Pool overview	Number
<b>Total Experts invited to be a grader</b>	<b>434</b>
Declined	22
Never answered	66
Accepted but did not complete the grading	23
<b>Completed grading</b>	<b>323</b>

## Digital Presentation format

Type of sessions	# Abstracts & Clinical Cases
Live Abstract sessions	141
Oral Abstracts - YIA	8
Oral Abstracts - NIA	4
e-Poster Presentation	739
Accepted withdrawn	79
<b>TOTAL ACCEPTED ABSTRACTS</b>	<b>971</b>
Live Clinical case session	18
Clinical cases Presentations	84
Clinical Case Award session	4
Accepted withdrawn	5
<b>TOTAL ACCEPTED CLINICAL CASES</b>	<b>111</b>

**971 ACCEPTED abstracts VS 892 PUBLISHED abstracts on the event platform = 79 ACCEPTED WITHDRAWN**



## Award Sessions: YIA clinical research, YIA Basic science, Nursing Investigator Award & Clinical Case Award

2021 winners:

Session Title	Role	Last Name	First Name	Country	Presentation Title	Eligibility criteria
Young Investigator Award: clinical research	FINALIST	Rodolico	Daniele	Italy	Target dose of heart failure medications is associated with better mortality/morbidity: data from the Swedish Heart Failure Registry	The first author/presenter must be 35 years old or less at the time of presentation.
	RUNNER UP 2	De Marzo	Vincenzo	Italy	Efficacy of additional medical therapies in patients with heart failure, a reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis	
	WINNER	Subramanian	Muthiah	India	<b>Effect of SGLT2 inhibitors on diastolic function in patients with non-obstructive hypertrophic cardiomyopathy</b>	
	RUNNER UP 1	Rettl	Rene	Austria	Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy	
Young Investigator Award: basic science	WINNER	Grote Beverborg	Niels	Netherlands (The)	<b>Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy</b>	The first author/presenter must be 35 years old or less at the time of presentation.
	RUNNER UP 2	Eaton	Deborah	USA	Cardiomyocyte function and myofilament calcium sensitivity are altered by HDAC inhibition	
	RUNNER UP 1	Nunez-Toldra	Raquel	UK & Northern Ireland	Mechanosensitive molecular mechanisms of myocardial fibrosis in living myocardial slices	
	FINALIST	Monguio-Tortajada	Marta	Spain	Extracellular vesicles from mesenchymal stromal cells combined with tissue engineering for myocardial repair	
Nursing Investigator Award	RUNNER UP 1	McDonagh	Julee	Australia	Correlation and agreement between subjective clinician-estimated frailty and a modified version of the frailty phenotype in adults with heart failure: a cross-sectional study.	Reserved for registered nurses and allied professionals within 5 years after confirmation of their PhD.
	FINALIST	Durante	Angela	Italy	Care dependency levels of heart failure patients: psychometric testing and congruence analysis within dyads	
	RUNNER UP 2	Cehade	Mireille	Lebanon	Lived experiences of left ventricular assist device patient caregiver dyads	
	WINNER	Lawson	Claire	UK & Northern Ireland	<b>16-year trends in 30-day cause specific readmissions following hospitalisation for heart failure in England by sex, socioeconomic status and ethnicity.</b>	
Clinical Case Award	FINALIST	Hobson	Simon	UK & Northern Ireland	Acute heart failure secondary to Multisystem Inflammatory Syndrome in Adults (MIS-A) temporally associated with asymptomatic SARS-CoV-2 infection.	
	RUNNER UP 1	Morris	Joseph	Ireland	Never Too Late to be Just in Time: Fulminant Giant Cell Myocarditis.	
	WINNER	Dominguez Rodriguez	Luis Manuel	Spain	<b>Severe ventricular dysfunction due to a catecholamine-secreting paraganglioma.</b>	

	RUNNER UP 2	Haegler- Laube	Eva	Switzerland	Nivolumab associated myasthenia gravis with severely elevated cardiac biomarkers: to treat or not to treat?	
--	----------------	-------------------	-----	-------------	---	--

### Jury Members:

Session Title	Role	Last Name	First Name	City	Country
Young Investigator Award: clinical research	Judge Abstract	Cannata	Antonio	Trieste	Italy
	Judge Abstract	Jankowska	Ewa Anita	Wroclaw	Poland
Young Investigator Award: basic science	Judge Abstract	Maack	Christoph	Wuerzburg	Germany
	Judge Abstract	Eschenhagen	Thomas	Hamburg	Germany
	Judge Abstract	Balligand	Jean-Luc	Brussels	Belgium
Nursing Investigator Award	Judge Abstract	Rakischeva	Amina	Almaty	Kazakhstan
	Judge Abstract	Neubeck	Lis	Edinburgh	UK & Northern Ireland
	Judge Abstract	Hill	Loreena	County Antrim	UK & Northern Ireland
Clinical Case Award	Judge Abstract	Volterrani	Maurizio	Rome	Italy
	Judge Abstract	Seferovic	Petar	Belgrade	Serbia
	Judge Abstract	Hill	Loreena	County Antrim	UK & Northern Ireland

### Abstract & Clinical Case Presenters Profile

#### Country representation

Country	# Abstract presenters	# Clinical case presenters
Algeria	2	0
Argentina	9	1
Armenia	2	0
Australia	4	1
Austria	10	1
Azerbaijan	0	1
Belarus	8	0
Belgium	8	0
Brazil	7	1
Bulgaria	3	0
Canada	8	0
China	4	0
Colombia	2	0
Croatia	4	0
Cyprus	1	0
Czechia	1	0
Denmark	3	0



Egypt	3	0
Finland	1	0
France	10	2
Georgia	2	0
Germany	32	4
Greece	17	1
Guinea	1	0
Hong Kong	2	1
Hungary	5	2
Iceland	1	0
India	7	1
Indonesia	5	1
Iraq	3	0
Ireland	11	3
Israel	5	2
Italy	66	12
Japan	4	3
Kazakhstan	1	0
Korea (Republic of)	3	0
Kyrgyzstan	1	0
Lebanon	3	3
Lithuania	4	2
Malta	3	0
Mexico	3	4
Moldova (Republic of)	3	0
Morocco	8	0
Netherlands (The)	28	1
North Macedonia	1	0
Norway	3	1
Peru	2	1
Poland	22	3
Portugal	128	25
Romania	11	7
Russian Federation	140	2
Saudi Arabia	1	0
Serbia	4	0
Singapore	4	2
Slovakia	2	0
Slovenia	2	0
South Africa	3	1
Spain	99	13
Sweden	8	3
Switzerland	4	2
Taiwan	1	0
Thailand	7	0
Tunisia	5	0
Turkey	11	0

Ukraine	22	3
United Arab Emirates	2	1
UK & Northern Ireland	49	11
United States of America	51	8
Uzbekistan	0	1
Viet Nam	2	0
<b>Grand Total</b>	<b>892</b>	<b>131</b>

#### Presenters age group

Age range	Abstract presenters	%	Clinical Case presenters	%
<b>35 and under</b>	<b>558</b>	<b>63%</b>	94	72%
36 to 40	113	13%	9	7%
41 to 46	73	8%	4	3%
47 to 57	103	12%	14	11%
58 & above	45	5%	10	8%
<b>Grand Total</b>	<b>892</b>	<b>100%</b>	<b>131</b>	<b>100%</b>

## Gender Representation

Gender	Abstract presenters	%	Clinical case presenters	%
Female	446	50%	65	50%
Male	446	50%	66	50%
<b>Grand Total</b>	<b>892</b>	<b>100%</b>	<b>131</b>	<b>100%</b>

## Abstract gallery

**Concept** - Accepted abstracts were published on the dedicated congress platform in various formats (see table below). This platform allowed for continued discussions during the event, with interaction functionalities such as rating the presentation, number of views, chat and comments.

Session type	# Sessions	Total Number of Abstracts/Cases	Maximum number of slides to be uploaded including the title one	Commentary recording	Commentary recording Max Duration	WEBCAM
Award Sessions	4	16	14	MANDATORY	10mns	MANDATORY
Live Abstract Sessions	16	141	6	MANDATORY	6mns	OPTIONAL
Clinical Cases	1	84	6	MANDATORY	6mns	OPTIONAL
Live Clinical Case Sessions	2	18	6	MANDATORY	6mns	OPTIONAL
ePosters	1	739	1	MANDATORY	3mns	NONE

## Resources were sorted by Session Type, Topic / Most Viewed / Best Rated

The screenshot displays the 'Heart Failure 2021' online congress platform. At the top, there are navigation links for 'Broadcast', 'Abstracts', 'Exhibition', 'HFA Booth', and 'Online Support'. A search bar is visible on the right. Below the navigation, the main heading is 'Abstracts, Clinical Cases and Latest Science'. Underneath, there are two sections: 'Browse by Session Type' with buttons for 'Registry Session', 'Abstract Sessions', 'Award Sessions', 'Clinical Cases', 'Clinical Trial Update', and 'E-Posters'; and 'Search by Topic' with buttons for various medical topics like 'Interventional Cardiology And Cardiovascular Surgery', 'Preventive Cardiology', etc. The 'Most viewed' section features a grid of abstract cards, each with a title, author name, and engagement metrics (likes, views, comments).


## e. Live zoom abstracts

### Overview – Table on topic & attendance

Session Number	Type	Topic	Title	Date & StartTime	Max attendance
508	Abstract	15.1 - Pathophysiology and Mechanisms	Chronic Heart Failure - Pathophysiology and Mechanisms 1	29/06/2021 14:00	384
510	Abstract	15.2 - Epidemiology, Prognosis, Outcome	Chronic Heart Failure - Epidemiology, Prognosis, Outcome	29/06/2021 14:00	160
506	Abstract	16 - Acute Heart Failure	Acute Heart Failure - Epidemiology, Prognosis, Outcome	29/06/2021 14:00	126
502	Abstract	35 - Cardiovascular Disease in Special Populations	Risk Factors and Prevention, Rehabilitation and Sports Cardiology, Cardiovascular Disease in Special Populations	29/06/2021 14:00	88
501	Abstract	41 - Basic Science	Basic Science	29/06/2021 14:00	55
505	Clinical Cases	15 - Chronic Heart Failure	Clinical Cases: Chronic Heart Failure and Comorbidities	29/06/2021 14:00	131
509	Abstract	15.1 - Pathophysiology and Mechanisms	Chronic Heart Failure - Pathophysiology and Mechanisms 2	30/06/2021 14:00	190
512	Abstract	15.4 - Treatment	Chronic Heart Failure - Treatment 1	30/06/2021 14:00	196
507	Abstract	16 - Acute Heart Failure	Acute Heart Failure - Diagnostic and Clinic	30/06/2021 14:00	123
515	Abstract	17 - Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)	Coronary Artery Disease, Acute Coronary Syndromes and Cardiogenic Shock	30/06/2021 14:00	63
516	Abstract	22 - Myocardial Disease	Myocardial Disease	30/06/2021 14:00	70
503	Abstract	37 - Cardiovascular Nursing and Allied Professions	Cardiovascular Nursing and Allied Professions, e-Cardiology/Digital Health, Research Methodology	30/06/2021 14:00	68
514	Abstract	10 - Atrial Fibrillation (AF)	Atrial Fibrillation and Device Therapy	01/07/2021 14:00	38
511	Abstract	15.3 - Diagnostic Methods	Chronic Heart Failure - Diagnostic Methods	01/07/2021 14:00	182
513	Abstract	15.4 - Treatment	Chronic Heart Failure - Treatment 2	01/07/2021 14:00	141
517	Abstract	20 - Valvular Heart Disease	Valvular Heart Disease and Interventional Cardiology	01/07/2021 14:00	44
518	Abstract	26 - Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure	Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure and Hypertension	01/07/2021 14:00	69
504	Clinical Cases	16 - Acute Heart Failure	Clinical Cases: Acute Heart Failure	01/07/2021 14:00	79

### Capture of a Live Abstract discussion room:

The 2 hosts and Presenters activate their webcam, whereas the audience is blinded but can activate their webcam if they wish and unmute their microphone to ask questions



#### f. Publications (abstract supplement)

All accepted abstracts will be published in the abstract supplement of the European Journal of Heart Failure.

(See schedule below)

<b>Production Stage</b>	<b>Date</b>
<b>Copy into production</b>	6-Jul-21
<b>To setter (service level)</b>	8-Jul-21
<b>Proofs Out</b>	29-Jul-21
<b>Proof Corrections due</b>	5-Aug-21
<b>Make up in</b>	9-Aug-21
<b>Revises out</b>	18-Aug-21
<b>Corrections for Rev due</b>	25-Aug-21
<b>Revised corrections to typesetter</b>	8-Sep-21
<b>Press files for approval</b>	13-Sep-21
<b>Approval from client due</b>	15-Sep-21
<b>Due online</b>	27-Sep-21

Abstracts were published on the congress dedicated platform during and after the event (event platform closed on 16 July).

Abstracts are also published on ESC 365.

## 4. INTERLUDES

Different items were used to entertain the audience before, during (during breaks) and after the congress: waiting slides, session openings and promotional videos.

Specific visuals were created for the Studio to enhance the viewer experience.

### a. Slides (waiting, transition, technical)

These slides are used either at the beginning or at the end of the daily programme.

- Starting at 08:00 CEST (not visible to the audience)
- Starting at 08:00 CEST (Studio version) (not visible to the audience)
- See you tomorrow (Studio version) (557 unique viewers)
- Save the date - HF 2022 (1,049 unique viewers)
- Join us on the: Main Channel at 14:10 CEST (229 unique viewers)
- Thank you / Access all resources here (Studio version) (264 unique viewers)
- Transition slide INTRO (Studio version) (1,699 unique viewers)
- Transition slide OUTRO (Studio version) (1,998 unique viewers)
- Curtain video IN (829 unique viewers)
- Curtain video OUT (916 unique viewers)

The technical slide was prepared for the ESC AV team and suppliers in case there is an issue with the video broadcast.

### b. Interludes (promo videos) and daily countdowns

The following videos were broadcast between scientific sessions to promote association or ESC content/products.

Code	Video title	Video duration (hh:mm:ss)	Tue. 29 June Unique viewers	Wed.30 June Unique viewers	Thr. 1 July Unique viewers	Occurrence	TOTAL Unique viewers
CD_1a	Daily count down	00:05:00	14	96	32	6	136
CD_1b	Daily count down (Studio version)	00:05:05	86	83	133	6	266
Inter_1	HFA Corpo_Membership	00:00:36	1,318	1,062	948	31	1,983
Inter_2	HFA Education	00:01:02	1,536	1,041	950	29	2,171
Inter_3	HFA Publications	00:00:46	914	1,177	796	25	1,753
Inter_4	HeartFailureMatters	00:02:19	1,053	436	868	18	1,607
Inter_5	ESC 365	00:00:39	1,066	967	617	20	1,708
Inter_6	ESC Pocket Guidelines	00:00:54	1,349	915	783	20	1,990

Code	Video title	Video duration (hh:mm:ss)	Tue. 29 June Unique viewers	Wed.30 June Unique viewers	Thr. 1 July Unique viewers	Occurrence	TOTAL Unique viewers
Inter_7	ESC - Our diversity (a unique community)	00:00:45	901	639	739	14	1,526
Inter_8	ESC Advocacy	00:00:53	544	555	440	9	1,089
Inter_9	ESC Congress 2021 promo	00:00:53	778	658	455	12	1448
Inter_10a	Stay tuned - looped version "Short break"	00:03:50	1,974	1,622	1,340	77	2,713
Inter_10b	Time for a break - looped version "Back at 09:50 CEST"	00:03:50	149	-	-	2	149
Inter_10c	Time for a break - looped version "Back at 10:25 CEST"	00:03:50	-	48	201	3	232
Inter_10d	Time for a break - looped version "Back at 14:10 CEST"	00:03:50	-	-	-	0	-
Inter_10e	Time for a break - looped version "Back at 15:00 CEST"	00:03:50	-	332	-	3	332
Inter_10f	Time for a break - looped version "Back at 14:10 CEST" (Studio version)	00:15:00	246	413	452	3	862

### c. Intro/outro

These intro videos, as well as outro videos and industry intro/outro, are used to introduce a session and frame it.

Specific intros and outros were also produced by STS Communication for the Studio:

- Inaugural session intro
- Inaugural session outro
- President intro
- Scientific session intro
- Scientific session outro

No independent statistics are available as these videos are included in the full session duration.



#### d. Advertorial Broadcasts

Four industry related videos were promoted during the congress.

Code	Video title	Video duration (hh:mm:ss)	Tue. 29 June Unique viewers	Wed.30 June Unique viewers	Thr. 1 July Unique viewers	Occurrence	TOTAL Unique viewers
AB_Astra Zeneca_1	THRIVE Advert broadcast 1 ---> Tuesday 11:40 HF Studio	00:00:20	266	-	-	1	266
AB_Astra Zeneca_2	THRIVE Advert broadcast 2 ---> Tuesday 16:05 HF Studio	00:00:20	540	-	-	1	540
AB_Ast3a Zeneca_4	SGLT2i Video --> Tuesday before 09:15	00:00:15	103	-	-	1	103
AB_Astra Zeneca_1	HiK symposium_video (RAASi) --> Tuesday before 11:40	00:00:15	112	-	-	1	112

# 5. INDUSTRY



## a. Exhibition

3 Exhibitor packages were available to industry partners wishing to exhibit at Heart Failure 2021. Each package enabled exhibitors to provide company information, promotional and scientific content (videos, pdf, links to external websites and a selection of their on-demand videos) as well as the opportunity for interaction with delegates (chat, book an appointment functionalities).

A total of 20 Packages were purchased by 19 Industries

Package type	Quantity
Starter	11
Booster	4
Expert	5
<b>Total</b>	<b>20</b>

In addition, 4 exhibitors ordered the Virtual Booth Insert to promote their external virtual booth / microsite on the congress platform.





## b. Industry Sponsored Sessions

In total, 25 Industry Sponsored Sessions were organised by 17 sponsors as well as one Tutorial.

### Overview of industry sponsored sessions

Channel	Day & Time Slot	Number of Live Viewers	Median Viewing Time
Channel - Chronic Heart Failure	Tuesday 29/06/21 11:40-12:25	187	21:00
Channel - Specials	Tuesday 29/06/21 11:40-12:25	82	31:00
Channel - Specials	Thursday 01/07/21 11:20 - 12:05	94	14:00
Across All Channels	EXCLUSIVE Wednesday 30/06/21 18:20-19:05	413	27:53
Channel - HF Studio	EXCLUSIVE Thursday 01/07/21 16:05 - 16:35	450	29:53
Channel - Acute HF	EXCLUSIVE Thursday 01/07/21 17:45-18:30	386	44:07
Channel - Chronic Heart Failure	Tuesday 29/06/21 09:15-09:45	203	11:43
Channel - HF Studio	EXCLUSIVE Tuesday 29/06/21 17:45-18:30	488	41:28
Channel - HF Studio	Wednesday 30/06/21 09:50-10:20	352	29:23
Across All Channels	EXCLUSIVE Wednesday 30/06/21 16:50-17:20	537	29:24
Channel - Chronic Heart Failure	Wednesday 30/06/21 09:50-10:20	221	24:13
Channel - Chronic Heart Failure	Thursday 01/07/21 09:50 - 10:20	204	23:27
Channel - Specials	Wednesday 30/06/21 11:20-12:05	68	23:06
Channel - HF Studio	Tuesday 29/06/21 11:40-12:25	328	21:48
Channel - HF Studio	Tuesday 29/06/21 09:15-09:45	277	21:02
Channel - Heart Failure	Thursday 01/07/21 11:20 - 12:05	92	36:32
Channel - HF Studio	EXCLUSIVE Tuesday 29/06/21 16:05 - 16:35	574	26:00
Channel - HF Studio	Thursday 01/07/21 11:20 - 12:05	394	39:25
Channel - Chronic Heart Failure	Wednesday 30/06/21 11:20-12:05	147	39:33
Channel - Acute HF	Tuesday 29/06/21 11:40-12:25	188	27:48
Channel - Acute HF	Wednesday 30/06/21 11:20-12:05	157	33:52
Channel - Acute HF	Wednesday 30/06/21 09:50-10:20	116	25:37
Channel - HF Studio	Wednesday 30/06/21 11:20-12:05	344	40:40
Channel - Chronic Heart Failure	Thursday 01/07/21 11:20 - 12:05	352	29:23
Channel - HF Studio	Thursday 01/07/21 09:50 - 10:20	319	29:26

## c. Sponsorship

Our sponsorship opportunities allowed industry partners to promote their activities before, during and after the congress.

### i. Eblasts

Promotional eBlasts were sent on the following dates:

- Pre-Event eBlast: 25 June
- Event eBlasts: 29 June, 30 June and 1 July
- Post-Event eBlast: 8 July

The image displays three promotional eblast screenshots for the Heart Failure 2021 World Congress on Acute Heart Failure. Each eblast features the event logo, dates (29 June - 1 July ONLINE CONGRESS), and various promotional messages and session listings.

**Eblast 1 (Left):** Headline: "Don't miss #HeartFailure2021". Key message: "Make room in your agenda for the latest clinical advances from industry partners!". Content includes: "From 29 June to 01 July, tune in for a series of live presentations from experts in cardiology as they discuss strategies for a universal approach towards the prevention and treatment of heart failure, network with peers and much more! No matter where you are, you will be able to connect to the digital platform." and "Book the following sessions from our industry partners in your calendar today to find out more about their groundbreaking research and therapies in the field." It lists several sessions with titles like "Find the balance between SGLT2 therapy and colchicine" and "SGLT2 inhibitors: optimising heart failure treatment".

**Eblast 2 (Middle):** Headline: "Don't miss #HeartFailure2021". Key message: "Get the latest available industry knowledge!". Content includes: "Dear Dr Merolf," and "Our online congress is now underway! No matter where you are, connect to the digital platform and tune in for a series of live presentations from experts in cardiology, network with peers and much more!". It also lists sessions such as "Join us for a Satellite Symposium today!" and "Can you help your HF patients dig out of despair, the longer, and feel better right from the start?".

**Eblast 3 (Right):** Headline: "Don't miss #HeartFailure2021". Key message: "Relive all of our sessions on demand!". Content includes: "Dear Doctor Hussain," and "Couldn't catch all of our Live Programme? Our live event was just the start of the experience! All on-demand content from Heart Failure 2021 is now available on our online platform to registered attendees until 16 July, which means that you can watch the sessions you missed or replay presentations of particular interest - all at your convenience." It lists sessions like "Defining HF care through chronic IC control - time to get practical" and "SGLT2 INHIBITION IN HEART FAILURE: WHAT HAVE WE LEARNED SO FAR?".

Each eblast concludes with a disclaimer: "This is a sponsored message and does not necessarily reflect the opinion of the ESC, nor does it engage its responsibility." and the ESC logo with the tagline "Our Diversity is Our Strength".

### ii. Banners

One banner on the homepage and two banners on the exhibition section were used by sponsors. The banners were visible only during the Congress dates from 29 June to 01 July.

### iii. Advert Broadcast

Advert Broadcasts are short videos promoting Satellite Symposia during the congress programme. One package was sold at Heart Failure 2021. The sponsor had 4 spots to promote their activities on Tuesday 29 June:

- 2 in the Chronic Heart Failure Channel
- 1 in the morning programme From the Studio channel
- 1 in the afternoon programme From the Studio Channel.

## 6. REGISTRATION, ATTENDANCE & PARTICIPATION

### a. Registration

Registrations	
Full Congress	5,215
A Taste Of	1,768
<b>Total active delegates</b>	<b>6,983</b>
Delegates registered for both	181
Group vouchers not activated	1,011
<b>Total registrations</b>	<b>8,175</b>

### b. Live programme attendance & participation

There were 2 separate registrations for HF 2021 – registration for the full event and a free ‘Taste of Heart Failure’ registration which gave limited access to the event.

- A total of **6,983** delegates registered from **142** countries/territories.



Registered Delegates	
Full Congress	5,215
A Taste Of	1,768
<b>Total</b>	<b>6,983</b>

\* where the same delegate had registered for both, we have only included them in the 'Full Congress' figure




- 71% of registered delegates came from National Cardiac Society Countries**
- 25% from Affiliated Cardiac Society countries**

Country	Registered	% of total
Spain	443	6.3%
Italy	429	6.1%
Germany	421	6.0%
United Kingdom	391	5.6%
Portugal	297	4.3%
Netherlands (The)	258	3.7%
Romania	250	3.6%
United States of America	225	3.2%
India	185	2.6%
France	178	2.5%





- **46%** of registrants under 40
- **46%** of registrants were female



## Delegates

The live programme ran over 3 days from 08:00 on 29 June to 21:45 on 1 July 2021. A delegate is defined as someone logged in to the congress platform to view content between these times.

- **3,884** delegates logged onto the Congress platform during the event
- **3,364** delegates attended the live programme over the course of the event

	29 June	30 June	1 July	Total
Total event attendees	2,881	2,525	2,290	3,884
Live channel viewers	2,535	2,068	1,857	3,364


- The Main Channel was the most popular live broadcast channel on each of the 3 days

Channel	29 June	30 June	1 July	Total
Main Channel – HF Studio	2,355	1,759	1,734	3,106
Chronic Heart Failure	825	980	612	1,646
Acute Heart Failure	405	814		1,045
Heart Failure			321	321
Specials	300	528	309	886
<b>Grand Total</b>	<b>2,535</b>	<b>2,068</b>	<b>1,857</b>	<b>3,364</b>

Top 10 countries	Delegates	% of total delegates
Germany	269	6.93%
United Kingdom of Great Britain and Northern Ireland	231	5.95%
Spain	220	5.66%
Italy	184	4.74%
Portugal	181	4.66%
Netherlands (The)	179	4.61%
Romania	175	4.51%
France	113	2.91%
Austria	113	2.91%
Switzerland	112	2.88%

## Event attendees



- 3,364** logged on to the congress platform and watched sessions live during congress hours.
- A further **520** delegates logged on to the congress platform during congress hours and only viewed on-demand content.
- In total, 3,884** logged on to the congress platform during the congress hours and watched live and/or on demand sessions.







## Attendee profiles

- **3,884** delegates from **113** countries/territories logged on to the congress platform during the congress times and watched live and/or on-demand sessions.
- **74%** from National Cardiac Society countries
- **22%** of delegates came from Affiliated Cardiac Society countries
- **3%** from rest of world countries



- **50%** of delegates were female and **44%** of delegates were under 40





- **53%** of delegates were practising cardiology physicians
- **17%** of delegates were students or in training




	Practicing	In training	Student	Retired	Unknown	Total	
Physician Cardiologist	1685	336	28	16	1	2066	53.2%
Other	456	80	43	6		585	15.1%
Physician (non-cardiologist)	174	62	21	7		264	6.8%
Allied Professional	134	21	16	4	1	176	4.5%
Nurse	110	5	4			119	3.1%
Unknown	1	4	42	1	626	674	17.4%
Total	2560	508	154	34	628	3884	
	65.9%	13.1%	4.0%	0.9%	16.2%		



- **51%** of delegates work in a hospital setting (note that a single delegate can work in more than one setting)




## 7. E-COMMUNICATION



### a. Promotional campaigns




Channel	Content	Results
Slider Home		
HFA Bulletin		<p>Sent to: 44,049</p> <p>Open: 7,562</p> <p>Clicks: 1,202</p>

<p>Dedicated email</p>		<p>Sent to: 68,292</p> <p>Open: 16,333</p> <p>Clicks: 1,216</p>
<p>HFA Bulletin</p>		<p>Sent to: 44,283</p> <p>Open: 7,365</p> <p>Clicks: 1,276</p>
<p>Dedicated email</p>		<p>Sent to: 68,204</p> <p>Open: 16,068</p> <p>Clicks: 1,169</p>



Slider home		
HFA Bulletin	<p><b>Congresses</b></p> <p><b>Heart Failure 2021</b> 29 June - 1 July ONLINE CONGRESS</p> <p><b>Get noticed</b> Heart Failure 2021 is the best stage to introduce your science to the heart failure world and be acknowledged by your peers</p> <p>Participate in the award competitions and qualify for a monetary prize and a free registration for Heart Failure 2021.</p> <p>Give your research longterm exposure and get published in:</p> <ul style="list-style-type: none"> <li>• The European Journal of Heart Failure, the online supplement</li> <li>• ESC Clinical Case Gallery - Heart Failure</li> </ul> <p><a href="#">Submit your abstract or clinical case</a> until 11 March.</p>	<p>Sent to: 44,397</p> <p>Open: 11,405</p> <p>Clicks: 1,193</p>
My ESC News	<p><b>Other Upcoming Deadlines</b></p> <p><b>Heart Failure 2021 Online &amp; on demand</b> Science Submission: tomorrow 11 March</p>	
Dedicated Email		<p>Sent to: 68,013</p> <p>Open: 14,892</p> <p>Clicks: 1,098</p>




My ESC News	<p><b>Heart Failure 2021</b> Abstract Submission Extended: 25 March</p>	Sent to: 156,955 Open: 23,258 Clicks: 4,677
My ESC News	<p>Heart Failure 2021</p>  <p><b>Deadline TOMORROW</b> Your research could change the world of heart failure so make sure it gets the recognition it deserves. Submit your abstract by 25 March.</p>	Sent to: 157,769 Open: 22,809 Clicks: 4,499
HFA Member Newsletter	<p><b>Congresses</b></p>  <p><b>Heart Failure Congress 2021 – Online and On Demand</b> Do you have great Late Breaking Science in the pipeline? <a href="#">Get it featured</a> in the programme of Heart Failure 2021, the world's leading congress in heart failure management. The deadline is 29 April. Don't forget that you can save today by taking advantage of the early registration fee if you sign up before 29 April. <a href="#">Register</a></p>	Sent to: 5,612 Open: 1,561 Clicks: 427
My ESC News	<p><b>Heart Failure 2021</b> Early Registration Savings: 29 April Late-Breaking Science Submission: 29 April</p>	Sent to: 159,609 Open: 23,085 Clicks: 3,852
HFA Bulletin	<p><b>Heart Failure 2021</b></p>  <p><b>Save your seat today!</b> From 29 June to 1 July, join more than 230 international speakers who will share their insights on heart failure management. Explore the <a href="#">scientific programme</a> and bookmark the sessions you don't want to miss. <a href="#">Register</a> by 29 April to get the best rate!</p>	Sent to: 44,644 Open: 10,395 Clicks: 837



<p>Dedicated email</p>		<p>Sent to: 68,413</p> <p>Open: 15,039</p> <p>Clicks: 1,767</p>
<p>Promotional toolkit email</p>		<p>Sent to: 407</p> <p>Open: 254</p> <p>Clicks: 34</p>
<p>My ESC News</p>	<p>Other Upcoming Deadlines</p> <p><b>Heart Failure 2021</b>  Early Registration Savings: 29 April  Late-Breaking Science Submission: 29 April</p>	<p>Sent to: 160,852</p> <p>Open: 22,908</p> <p>Clicks: 2,918</p>
<p>HFA Bulletin</p>		<p>Sent to: 44,743</p> <p>Open: 11,174</p> <p>Clicks: 1,447</p>

<p>Dedicated email</p>		<p>Sent to: 21,120</p> <p>Open: 5,597</p> <p>Clicks: 636</p>
<p>My ESC News</p>	<p><b>Online Congresses and Meetings</b></p> 	<p>Sent to: 163,478</p> <p>Open: 22,389</p> <p>Clicks: 2,466</p>
<p>Slider Home</p>		



<p>Dedicated email</p>		<p>Sent: 45,027</p> <p>Open: 7,490</p> <p>Clicks: 1,341</p>
<p>My ESC News</p>	<p>Other Upcoming Deadlines</p> <p><b>Heart Failure 2021</b> Live event 29 June - 1 July <a href="#">Register</a></p>	<p>Sent to: 165,202</p> <p>Open: 21,883</p> <p>Clicks: 2,551</p>
<p>Dedicated email</p>		<p>Sent to: 941</p> <p>Open: 548</p> <p>Clicks: 273</p>

<p>e-bulletin</p>		<p>Sent to: 3,911</p> <p>Open: 1,715</p> <p>Clicks: 918</p>
<p>My ESC News</p>		<p>Sent to: 166,207</p> <p>Open: 21,626</p> <p>Clicks: 2,309</p>
<p>e-bulletin</p>		<p>Sent to: 4,852</p> <p>Open: 2,351</p> <p>Clicks: 991</p>

<p>e-bulletin</p>		<p>Sent to: 65,787</p> <p>Open: 16,568</p> <p>Clicks: 1,434</p>
<p>e-bulletin</p>		<p>Sent to: 5,225</p> <p>Open: 2,415</p> <p>Clicks: 910</p>

b. Social media

iv. Twitter

### Key Metrics for Twitter

**1.76k**

Users

**5.64k**


Mentions

**31.3M**

Impressions

**2.48M**

Reach



June 26, 2021 - July 4, 2021

The Key metrics for twitter widget provides insight into both the trend over time as well as top level metrics for the volume of Twitter content over a given period.


### Top keywords



June 26, 2021 - July 4, 2021

The Top keywords widget provides insight into the most frequently used words and terms over a given time period.

## Top hashtags




June 26, 2021 - July 4, 2021

The Top hashtags widget provides insight into the hashtags that appear most frequently in social and editorial content over a given time period.

## Top Locations

Country ▾



June 26, 2021 - July 4, 2021

The Top locations widget provides insight into the geographic breakdown of social and editorial content over a given time period.

## Top 3 performing posts

- #HeartFailure2021 starting tomorrow 08:00 CET 🤗 Bookmark the platform <https://bit.ly/3y1TOfu> Make sure to register 😊 <https://bit.ly/3x8e6TR>

47,600 impressions

859 engagements

- #HeartFailure2021 is on #cardiotwitter 🤗 Follow our amazing Twitter Ambassadors

@HFA\_President @ACNAPPresident @HillLoreena @ShelleyZieroth @MihaiTrofenciu @paomorejón 🤝

for the most exciting updates in #heartfailure

46,962 impressions

408 engagements

3,307 media views

- #HeartFailure2021 Inaugural Session <http://bit.ly/3y1TOfu>

45,194 impressions

1,034 engagements

124 media views

## v. Facebook

### Top 3 performing posts

- Heart Failure friends, thank you for these three amazing days, direct from the #HeartFailure2021 studio in Florence 😊 Access resources on ESC 365 from July 16 Exclusive for HFA silver & gold members <https://bit.ly/3w7pxKF>

32,339 Reach

36,538 Impressions

- #HeartFailure2021 starting tomorrow 08:00 CET 🕒 Bookmark the platform <https://bit.ly/3jIQyaz> Make sure to register 😊 <https://bit.ly/3wcm1zp>

28,341 Reach

28,341 Impressions

- In case you missed this update 📌😊 #heartfailure2021

15,105 Reach

15,236 Impressions

## vi. LinkedIn

### Best performing posts

- #HeartFailure2021 starting tomorrow 08:00 CET Bookmark the platform <https://bit.ly/2UFM18t>

Make sure to register 😊 <https://bit.ly/3pFX9xJ>

16,029 Impressions

278 Reactions

- #HeartFailure2021 Live studio from Florence 29 June-1 July

120 scientific sessions <https://bit.ly/2Thpi1O>

Connect w/ Massimo Francesco Piepoli, Yuri Lopatin, Tiny Jaarsma, Shelley Zieroth, Gianluigi Savarese, Jelena Celutkiene & so many more #HeartFailure experts

Join us <https://bit.ly/3pFX9xJ>

8,785 Impressions

125 Reactions

2,055 Views

## **vii. Instagram**

### **Best performing posts**

- #heartfailure2021 deadline for abstracts & clinical cases is 11 March - Link in our bio.

Get the exposure your research deserves. Be published in #EJHF. Feature in ESC 365 online library & ESC Clinical Case Gallery - #HeartFailure. Winners and runners up of Award competitions will get a free registration to Heart Failure 2021 and monetary prize.

44,047 reach

46,478 impressions

- #HeartFailure friends, thank you for these three amazing days, direct from the #HeartFailure2021 studio in Florence 😊 Access resources on ESC 365 from July 16 Exclusive for HFA silver & gold members - Link in our bio

22,485 reach

17,139 impressions

- A unique opportunity to present and discuss your work in real-time with Europe's #HF heavyweights

This year, leaders in #HeartFailure will accompany you through your live presentation during #HeartFailure2021 Time to submit your abstract/clinical case. Deadline 25 March - Link in our bio

14,807 reach

16,263 impressions

## **viii. Metrics definition**

### **Impressions**

Number of times a post was displayed on feeds (estimation).

### **Engagement:**

Total number of times users interacted with a post; this includes all clicks anywhere on the post, comments, shares etc

### **Engagement rate:**

The number of engagements (retweets, comments, likes, shares, clicks on posts etc) divided by the total number of impressions

### **Reach:**

The number of unique users who saw a post (estimation).


### **Clicks:**

Clicks on weblinks (Twitter, Instagram) Clicks on posts (Facebook, Twitter)

### c. General Results

- **Clicks: 13,170** (Is counted when a person clicks the ad).
- **Impressions: 210,066** (Is counted when every time an ad is shown on a search result page)
- **CTR: 6.27%** (Is a ration showing how often people who see our ad end up actually clicking it).

#### Top Performing keywords:




#### Top Performing ads:

Ad	Clicks	Impr.	CTR
<p>Heart Failure 2021   29 June - 1 July   Three-days online congress  <a href="https://escardio.org/heartfailure/2021congress">escardio.org/heartfailure/2021congress</a>                      Cutting edge science through debates, symposia, special sessions, abstracts live sessions. Including Late Breaking Science, Parade of Device, Guidelines In Daily Practice</p>	3,285	55,287	5.94%
<p>Heart Failure 2021   29 June - 1 July   Greater savings by 29 April  <a href="https://escardio.org/heartfailure/2021congress">escardio.org/heartfailure/2021congress</a>                      Enjoy the lowest registration fee. Access scientific sessions, exhibition areas, replay of the congress ressources on ESC 365</p>	3,125	52,433	5.96%
<p>Heart Failure Congress   29 June - 1 July, 2021   Register today  <a href="https://escardio.org/heartfailure/2021congress">escardio.org/heartfailure/2021congress</a>                      3 days of live scientific and educational presentations. Earn CME credits for each full hour spent online, learning the latest trends on HF.</p>	2,686	91,819	2.93%
<p>Heart Failure 2021   29 June - 1 July -Register now   Join HF specialists virtually +2 more  <a href="https://escardio.org/heartfailure/2021congress">escardio.org/heartfailure/2021congress</a>                      Meet the brightest experts at the world's leading online event on heart failure. A unique international...  <a href="#">View assets details</a></p>	2,213	6,046	36.60%




## Breakdown by countries



## Device split:

 Mobile phones  Tablets  Computers




## 8. PRESS

### a. Key numbers

Press release	Date	Articles		Potential Reach
Heart Failure 2021	29 June- 1 July 2021	Total 192	Daily Mail New York Times Clarín La Repubblica	127 M
Heart failure is associated with an increased risk of cancer	28 June	93	Daily Mail MSN NZ New York Times Clarín	98 M
Worse outcomes observed after heart attacks during pandemic compared to previous year	29 June	32	ProKerala News Medical Healio	3,2M
Older patients with heart failure denied effective treatments	1 July	17	La Repubblica Medscape La Stampa	5,8M

\*These figures should just be taken as a useful indication of the impact of ESC press coverage. The estimation is delivered by SimilarWeb and Critical Mention.

## b. Charts



## c. Clippings

Outlet: Medscape, USA

News > Medscape Medical News > Conference News > ESC-HFA 2021

# Heart Failure Med Undertreatment Due to Older Age Common, Flouts Evidence

Steve Stiles

July 06, 2021

Read Comments      [Add to Email Alerts](#)

Advanced age by itself can be a reason physicians hold back on prescribing mainstay medications, or not uptitrate them per guidelines, to their older patients with heart failure (HF) and reduced ejection fraction (HFrEF), suggests a large cohort study.

About 80% of patients aged 80 years or older were prescribed renin-angiotensin-system inhibitors (RASi) in a multivariate-adjusted analysis of more than 27,000 patients in the Swedish Heart Failure Registry (SwedeHF). In contrast, such drugs — which included angiotensin receptor-neprilysin inhibitors (ARNi), angiotensin receptor blockers, and ACE inhibitors — were prescribed to 95% of patients younger than 70 years.

Similarly, fewer of the oldest patients were offered meds from the two other drug classes core to HF management at the time, beta blockers and mineralocorticoid receptor antagonists (MRA).

And among those in the 80-and-older age group who were prescribed RASi or beta blockers, their uptitration more often fell short of even half the target dosage, compared with the youngest patients in the analysis.

Physicians may hold back on full guideline-directed medical therapy in their very elderly patients with HFrEF for many reasons, including a perceived likelihood of drug intolerance due to frailty or multiple comorbidities, including renal dysfunction, Davide Stolfo, MD, Karolinska Institutet, Stockholm, Sweden, and University of Trieste, Italy, told *theheart.org* / *Medscape Cardiology*.


But the current analysis was adjusted for about 80 variables "that in our interpretation may be main reasons for not introducing drugs and using them in the older patients," he said. They included care setting (that is, inpatient or outpatient), HF severity by several measures, a range of comorbidities, renal dysfunction, and history of serious illness such as cancer.

Even then, age emerged as a significant, independent predictor of medical therapy underuse in the oldest patients. Some physicians apparently see advanced age, by itself, as an "intrinsic reason" not to abide by HFrEF medical therapy recommendations, said Stolfo, who presented the analysis last week at HFA 2021, the annual meeting of the Heart Failure Association of the European Society of Cardiology (ESC-HFA), conducted both virtually and live in Florence, Italy.

Most major HF-drug trials have excluded or admitted few patients aged 80 years or older, but "the guidelines recommend treatment regardless of age, and in the trials there has been no influence from age on the effectiveness of drugs," Stolfo observed.

# Heart Failure Tied to Increased Cancer Risk, Study Finds

People with heart failure may live for many years and should continue to get regular cancer screenings, experts say.



Chloe Cushman



By Nicholas Bakalar

July 19, 2021

People with heart failure may be at increased risk for cancer.

Cancer patients are usually monitored for heart failure because some cancer drugs can damage the heart. Now a new study suggests that heart failure patients, who may live for many years with the condition, might benefit by being monitored for cancer.

Researchers used a German health database to track 100,124 patients with heart failure, comparing them with the same number of controls who did not have heart failure. All were cancer-free at the start, and the scientists tracked their incidence of cancer over the following 10 years. [The study is in the journal ESC Heart Failure.](#)

The two groups were matched for age, sex, age, obesity and the incidence of diabetes, although the researchers lacked data on socioeconomic status, smoking, alcohol consumption and physical activity, which are all known to affect the risk for cancer.

Still, the differences in cancer incidence between the two groups



# Sportello Cuore

in collaborazione con



VAI ALLA HOMEPAGE DI SALUTE



Informazione pubblicitaria



**Media Contact Database**

Seamlessly Integrated with Critical Mention's Media Monitoring Platform

 Critical Mention Open

SPORTELLO CUORE

## Scompenso cardiaco, i grandi anziani curati meno dei giovani

DI FEDERICO MERETA



Anche se le linee guida non fanno differenze d'età una ricerca condotta in Svezia registra negli over 80 un minor ricorso a trattamenti farmacologici e non

06 Luglio 2021

2 minuti di lettura



Il cuore che "fatica" a svolgere il suo compito, giorno dopo giorno, perdendo progressivamente la sua capacità di "pompare" il sangue, è una realtà sempre più diffusa in un Paese che "invecchia". Lo dicono le cifre, che parlano dello scompenso cardiaco come di una condizione in costante aumento, che oggi interessa in Italia centinaia di migliaia di persone. Controllare la situazione attraverso farmaci specifici è fondamentale, soprattutto nelle prime fasi della patologia, così come conta moltissimo l'aderenza regolare alle cure.

### Approcci diversi in base all'età

Poi entrano in gioco anche i dispositivi medici, di "sostegno" all'azione del cuore. Ma è fondamentale che le terapie siano indicate, caso per caso, indipendentemente dall'età della persona che ha il cuore "stanco". E invece, forse non è sempre così. A porre l'attenzione sul tema è una ricerca condotta da **Davide Stolfo** dell'Istituto Karolinska di Stoccolma, presentata al congresso *Heart Failure 2021*, organizzato dalla Società Europea di Cardiologia. Il tutto, senza che le indicazioni internazionali sul trattamento della patologia indichino possibili "differenze" nell'approccio terapeutico in base all'età. "Le linee guida raccomandano gli stessi trattamenti per tutti i pazienti con insufficienza cardiaca indipendentemente dall'età - ricorda lo stesso Stolfo - la nostra analisi è stata aggiustata per altre condizioni che potrebbero giustificare la sospensione della terapia o la riduzione della

Informazione pubblicitaria



**Real-Time Media Monitoring**

- ✓ Track real-time media coverage
- ✓ Measure sentiment analysis & key analytics
- ✓ Share intuitive reports
- ✓ Grow your brand

[Get Started](#)

MEDICAL  
 HEALTH NEWS  
 SOCIAL MEDIA  
 BUSINESS COVERAGE

## SALUTE



### Reumatologia, i pazienti

## Salud

# La insuficiencia cardíaca se asocia con más riesgo de cáncer: cómo prevenirla

Lo halló un estudio de la Sociedad Europea de Cardiología. Hay medidas comunes que ayudan a ambos riesgos.



Las personas con insuficiencia cardíaca deben asistir a controles periódicos. Foto Shutterstock.



2020/2021-607 | Clarin.com Buena Vida | Actualizado el 20/09/2021 6:07

La **insuficiencia cardíaca (IC)** es una afección por la que el corazón no puede bombear sangre rica en oxígeno al resto del cuerpo en forma eficiente. Es un problema frecuente que puede tener múltiples causas. Y ahora un estudio realizado sobre más de 200.000 personas halló que se asocia con un **mayor riesgo de cáncer**.

La buena noticia es que hay **medidas comunes** que reducen el riesgo de desarrollar **algunos tipos de cáncer** vinculados a **hábitos no saludables** (como mala alimentación, sedentarismo, tabaquismo, entre otros) y que, a su vez, ayudan a prevenir la insuficiencia cardíaca.

Así lo expresó Marius Luedde, de la Universidad Christian Albrecht de Kiel y de la Práctica Grupel de Cardiología, en Bremerhaven, Alemania. "Este fue un estudio observacional y los resultados no prueban que la insuficiencia cardíaca cause cáncer", dijo. "Sin embargo, eñadid- los hallazgos sugieren que los pacientes con insuficiencia cardíaca pueden beneficiarse de los métodos de prevención del cáncer."

Luedde es uno de los autores del trabajo publicado en **ESC Heart Failure** y que se presenta hoy en Heart Failure 2021, un congreso de la Sociedad Europea de Cardiología (ESC, por sus siglas en inglés).



La hipertensión no controlada puede causar insuficiencia cardíaca. Foto Shutterstock.

### Una enfermedad muy prevalente

La insuficiencia cardíaca afecta a alrededor de **65 millones de personas** en todo el mundo. Las causas más comunes son la **enfermedad arterial coronaria**, la **hipertensión no controlada** y otros problemas del corazón (cardiopatías congénitas, **infarto**, infecciones, **arritmias**). La **anemia grave**, el **hipotiroidismo**, el **enfisema**, entre otras enfermedades, también pueden favorecer la IC.

### Las más leídas de Buena Vida

-  **Dermatología**  
Formación de arrugas y qué hacer al aplicarlas
-  **Mitos y tabúes**  
El cáncer para dermatólogos: el cáncer
-  **Coronavirus**  
COVID en la piel: las alteraciones cutáneas que puede producir
-  **Para adelgazar**  
¿Qué es la dieta keto y cómo funciona, día por día, recetas simples para aplicarla
-  **Para bajar de peso**  
Ayuda intermitente como en la dieta, cuánto con sus beneficios y qué se puede tomar

Outlet: DailyMail, United Kingdom

# MailOnline



Home **News** U.S. | Sport | TV&Showbiz | Australia | Femail | Health | Science | Money |  
Latest Headlines | Covid-19 | Princess Diana | Royal Family | Prince Harry | Meghan Markle | World News | He

## Heart failure could raise risk of developing cancer for thousands of patients, study suggests

- New study found heart failure patients may be more at risk of developing cancer
- Around 25% patients went on to get cancer, compared to 16% without condition
- Evidence suggests failing heart may produce proteins which cause inflammation

By VICTORIA ALLEN SCIENCE CORRESPONDENT FOR THE DAILY MAIL  
PUBLISHED: 05:15 BST, 28 June 2021 | UPDATED: 05:15 BST, 28 June 2021



**64**  
View comments

Heart failure may increase the risk of developing cancer, a study has found.

Up to 920,000 people in the UK are thought to be living with the condition, which happens when the heart is not pumping blood around the body as well as it should – often following damage to the organ’s muscles from a heart attack.

Now researchers who have been tracking people with heart failure over ten years have found they are more likely to be diagnosed with cancer.



The study of more than 200,000 people found around a quarter of heart failure patients went on to get cancer, compared to just 16 per cent of those without the heart condition.

